May 15, 2021 03:30 PM
Cipla had posted a consolidated net profit of Rs 412 crore in the March quarter of last fiscal. Net profit for the same period in 2019-20 was 73 per cent higher than Rs 238 crore. Total operating income rose to Rs 4,606 crore from Rs 4,376 crore. Consolidated net profit for the full financial year 2020-21 stood at Rs 2,389 crore. Profit of Rs 1,500 crore in 2019-20.
Total operating income rose to Rs 19,160 crore from Rs 17,132 crore. Domestic Prescription business grew 6 percent. Overall business in South Africa grew by 10 percent. U.S. business revenue was $ 138 million. The Board of Directors has recommended a dividend of Rs.5 per share with a face value of Rs.2.
Cipla Drug major Cipla on Friday posted 73 per cent rise in consolidated net profit at Rs 412 crore for the fourth quarter ended March 31, 2021 on the back of robust sales across markets.
The Mumbai-based firm had reported a net profit of Rs 238 crore in January-March 2019-20. Total revenue from operations rose to Rs 4,606 crore as compared with Rs 4,376 crore in the same period of 2019-20, Cipla said in a regulatory filing.
For the entire 2020-21 fiscal year, Cipla reported a consolidated net profit of Rs 2,389 crore as against Rs 1,500 crore in 2019-20. Total revenue from operations in the last fiscal year rose to Rs 19,160 crore as against Rs 17,132 crore in 2019-20.
The drug maker said its domestic prescription business grew 6 per cent while the overall business in South Africa rose 10 per cent on a year-on-year basis. Similarly, the US business reported USD 138 million in revenue.